Quidel Announces Timing of Filing of Form 8-K/A To Report Historical & Pro Forma Financial Information for Acquired Triage As...
December 13 2017 - 7:00PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced that it plans to file its
required report on Form 8-K/A with the Securities and Exchange
Commission (the “Commission”) after market close on Tuesday,
December 19, 2017. The Form 8-K/A will amend Quidel’s prior report
on Form 8-K filed with the Commission on October 6, 2017 that
related to Quidel’s completed acquisition of the Triage and BNP
Businesses. The amendment is expected to include the required
audited abbreviated statements of assets acquired and liabilities
assumed and of revenues and direct expenses of the Triage and BNP
Businesses together with the required pro forma information.
Following the reporting of the required financial statements and
pro forma information, Douglas Bryant, president and chief
executive officer, and Randy Steward, chief financial officer, will
host an investment community conference call on Wednesday, December
20, 2017 beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific
Time) to discuss the results and answer questions. During the
conference call, the company will also discuss business and
financial developments and trends. The company's statements may
contain or constitute material information that has not been
previously disclosed.
To participate in the live call by telephone from the U.S., dial
877-930-5791, or from outside the U.S., dial 253-336-7286, and
enter the audience pass code 667-9477.
A live webcast of the call can be accessed on the Investor
Relations section of the Quidel website
(http://ir.quidel.com). The website replay will be
available for 14 days. The telephone replay will be available for
48 hours beginning at 11:30 a.m. Eastern Time (8:30 a.m. Pacific
Time) on December 20, 2017 by dialing 855-859-2056 from the U.S.,
or by dialing 404-537-3406 for international callers, and entering
pass code 667-9477.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and
fecal occult blood. Quidel's recently acquired Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC),
offering a diverse immunoassay menu in a variety of tests to
provide you with diagnostic answers for quantitative BNP, CK-MB,
d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen.
Quidel’s research and development engine is also developing a
continuum of diagnostic solutions from advanced immunoassay to
molecular diagnostic tests to further improve the quality of
healthcare in physicians’ offices and hospital and reference
laboratories. For more information about Quidel’s comprehensive
product portfolio, visit quidel.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171213006119/en/
Quidel Contact:Quidel CorporationRandy StewardChief Financial
Officer(858) 552-7931orMedia and Investors Contact:Quidel
CorporationRuben Argueta(858) 646-8023rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Apr 2024 to May 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2023 to May 2024